ClinicalTrials.gg
Active, not recruitingNCT04881032NANO-GBMUpdated Oct 22, 2026

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

A Phase 1/2 interventional study of Polysiloxane Gd-Chelates based nanoparticles (AGuIX) and radiotherapy in Glioblastoma, sponsored by Centre Jean Perrin. Active, not recruiting at 9 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Jean Perrin · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.

Enrollment
79th of 131
66 · median 80
Started
2022
with 6 others
Phase 1/2
23 of 150
3 open now
Primary completion
2026-11
later than 14 of 50 live
Registered
108th of 150
by date

Among the 150 studies in Glioblastoma with a site in France, this one is the 79th largest by enrollment of the 131 interventional ones that give a count, is one of 7 that started in 2022, is one of 23 in phase 1/2, reaches primary completion later than 14 of the 50 other live ones, and was the 108th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Glioblastoma with a site in France, or all of them as a file.
02

Study summary

This is a phase I/II clinical trial evaluating the association of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma.

The primary objectives of this study were to determine the recommended dose of AGuIX in combination with radiotherapy and TMZ during the concomitant radiochemotherapy period (phase I) and to estimate the efficacy of the combination radiochemotherapy + AGuIX (recommended dose), measured by the 6-month progression-free survival rate (PFS) (phase II)

Three dose levels of intravenous AGuIX nanoparticles will be explored: 50 mg/kg, 75 mg/kg and 100 mg/kg.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of grade IV glioblastoma ( or partial surgery)
  • Patient not operated or partial resection
  • superior to 70%
  • Age between 18 years old and 75 years old
  • superior to 6 months
  • superior to 100,000 / mm3
  • PNN superior to 1500 / mm3
  • superior to 10 g / dL
  • Creatinine superior to 1.5 times the upper normal limit or clearance according to superior to 50 mL / min
  • Liver function (GGT, PAL, ASAT, ALAT, ) superior to 1.5 times the upper normal limit
  • For patients receiving treatment with , treatment with corticosteroids must be at a stable or decreasing dose for at least 14 days before inclusion
  • Patient able to swallow and retain oral medication
  • Negative serum pregnancy test within 7 days before the first administration of treatment for women
  • Women of and men whose partners are of childbearing potential must agree to use, themselves or their partners, an approved method of throughout the treatment and at least 6 months after the last administration of study treatment.
  • Obtaining signed from the patient
  • Patient affiliated to a social security regimen

Exclusion criteria

Exclusion Criteria:

  • prior brain radiotherapy
  • prior chemotherapy (including implants containing carmustine (Gliadel®) or immunotherapy (vaccination included)
  • Any to TMZ listed in the SPCs
  • History of major intestinal resection which may modify the absorption of oral drugs according to the judgment of the investigator
  • Diagnosed inflammatory bowel disease (Crohn disease or ulcerative colitis)
  • Diarrhea superior to grade 2 (whatever the cause)
  • Current or recent treatment with another drug or participation in another therapeutic clinical trial (within 30 days of inclusion).
  • History of other cancer in the 5 years preceding inclusion, except for basal cell carcinomas of the skin and in situ carcinomas of the cervix
  • Pregnant or breastfeeding women
  • Contraindication to MRI or gadolinium injection
  • History of severe anaphylactic reactions due to the injection of gadolinium-based contrast product (dotarem, etc.)
  • Patient under guardianship or curatorship
  • History of nephropathy
  • Psychological disorder or social or geographic reasons that may compromise medical monitoring of the trial or compliance with treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    AGuIX + chemoradiotherapy (radiotherapy + temozolomide)

    addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II

    Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX) · Radiation: radiotherapy · Drug: Temozolomide

  • Sham comparator
    chemoradiotherapy (radiotherapy + temozolomide)

    standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II

    Radiation: radiotherapy · Drug: Temozolomide

Interventions

  • DrugAGuIXStudies of AGuIXAGuIX pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose

  • Radiationradiotherapy

    60 Gy in 6 weeks

  • Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy. After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days .

06

What researchers measure

Primary outcomes

  1. The recommended dose (phase I) of AGuIX in combination with TMZ and and radiotherapy during the radio-chemotherapy period

    Only toxicities occurring during concomitant radiochemotherapy will be considered for the evaluation of Dose Limiting Toxicity radiotherapy during the radio-chemotherapy period is defined as the highest dose tested in which the % of dose-limiting toxicities (DLT) is less than 33%. DLT is defined as any grade 3-4 toxicity according to the NCI CTCAE v5.0 classification, except alopecia, nausea, and vomiting which can be quickly controlled with appropriate measures.

    Time frame: during 6 weeks after the first injection of AGuIX

  2. 6-month Progression Free Survival (PFS) rate (phase II)

    Time frame: 6 months from the start of treatment

Secondary outcomes

  1. Pharmacokinetic Cmax of AGuIX

    maximal plasma concentration (Cmax) of AGuIX

    Time frame: Day 0 , Day 7, Day 14

  2. Pharmacokinetic Tmax of AGuIX

    time of maximal plasma concentration (Tmax) of AGuIX

    Time frame: Day 0 , Day 7, Day 14

  3. Pharmacokinetic AUC of AGuIX

    Area Under the Curve (AUC) of AGuIX

    Time frame: Day 0 , Day 7, Day 14

  4. Pharmacokinetic t1/2 of AGuIX

    pharmacokinetic term half-life (t1/2) of AGuIX

    Time frame: Day 0 , Day 7, Day 14

  5. distribution of AGuIX

    measure of RMI contrast enhancement in tumor and healthy tissue

    Time frame: after the first and last injection of AGuIX, Week 0 and Day 14

  6. Overall Survival

    Time frame: from the start of treatment to death, up to 24 months

  7. Progression Free Survival (PFS)

    Time frame: from the start of treatment to progression, up to 24 months

  8. Toxicity (CTCAE criteria)

    according to NCI Common Toxicity Criteria for Adverse Effect (CTCAE) criteria

    Time frame: from baseline to 30 days after treatment (concomitant and adjuvant treatment) (week 35)

07

Study locations

9 sites
08

References and documents

Publications

  • Thivat E, Casile M, Moreau J, Molnar I, Dufort S, Seddik K, Le Duc G, De Beaumont O, Loeffler M, Durando X, Biau J. Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). BMC Cancer. 2023 Apr 15;23(1):344. doi: 10.1186/s12885-023-10829-y. PubMed 37060055 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 56 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Nov 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 11, 2021
StartActual
Mar 7, 2022
Primary completionEst.
Nov 2026was Sep 2025
CompletionEst.
Mar 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2025→Nov 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Sep 2025→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04881032
Lead sponsor
Centre Jean Perrin
Collaborators
Ministry for Health and Solidarity, France
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Mar 7, 2022
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Juliette Moreau, Md
principal investigator · Centre Jean Perrin

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGuIX

Start the discussion